| abstract |
The present invention relates to novel compounds of formula (I) or a pharmaceutically acceptable salt thereof: n n n n n n n n n n whereinn R 1 is hydrogen or C 1-4 alkyl; R 2 is C 1-4 alkyl; R 3 is hydrogen, or a phenyl group, a heterocyclyl group, a 5- or 6-membered heteroaromatic group, or a 8- to 11-membered bicyclic group, any of which groups is optionally substituted by 1, 2, 3 or 4 substituents selected from the group consisting of: halogen, cyano, C 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkanoyl and SF 5 ; p is 0, 1, 2, 3 or 4; and R 4 is independently selected from a group consisting of: halogen, hydroxy, cyano, C 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkoxy, haloC 1-4 alkoxy and C 1-4 alkanoyl; n is 0 or 1;n nwherein when R 4 is chlorine and p is 1, such R 4 is not present in the ortho position with respect to the linking bond to the rest of the molecule;n nand wherein, if n is 0, R 3 comprises at least one SF 5 group as a substituent; processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as modulators of dopamine D 3 receptors, e.g. to treat drug dependency, as antipsychotic agents, to treat obsessive compulsive spectrum disorders, premature ejaculation or cognition impairment. |